Study Details

Back to Search Results

A Study to Assess the Safety, Pharmacokinetics and Effectiveness of AGS-16C3F Monotherapy in Subjects with Renal Cell Carcinoma (RCC) of Clear Cell or Papillary Histology

This trial is complete
The study has ended normally, and participants are no longer being examined or treated (that is, the last participant's last visit has occurred).

Clinicaltrials.gov ID

The unique identification code given to each clinical study upon registration at ClinicalTrials.gov.
NCT01672775

Astellas Study ID

The unique identification code given by the study sponsor.

AGS-16C3F-12-2

EudraCT ID

The unique identification code given to each clinical study upon registration at EudraCT (European Union Drug Regulating Authorities Clinical Trials Database).

N/A

Follow Trial

Condition

Kidney Cancer

Phase

These clinical trials are usually the first time an experimental treatment is studied in a small group of people.

Phase 1

Age

18 years - N/A

Sex

Female & Male

Product

N/A

Type

A type of clinical study in which participants are assigned to groups that receive one or more intervention/treatment (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes.

Interventional

Trial Dates

Jul 2012 - Feb 2017

Masking

None (Open Label)

Enrollment number

34

A Phase 1, Open Label, Multi-center Study to Assess the Safety, Pharmacokinetics and Effectiveness of AGS-16C3F Monotherapy in Subjects with Renal Cell Carcinoma (RCC) of Clear Cell or Papillary Histology

Study summary

Study documents

Study Documents, including study results, are available after a study is completed or terminated, according to Astellas Transparency policy.

Get More Information

Would you like more information about clinical trial sites that are recruiting participants for A Study to Assess the Safety, Pharmacokinetics and Effectiveness of AGS-16C3F Monotherapy in Subjects with Renal Cell Carcinoma (RCC) of Clear Cell or Papillary Histology? Contact us by filling our your information to the right and we’ll respond to you.

By clicking ["Continue/Submit"], you agree that Astellas may contact you by email with information to help you connect with clinical trial sites. While we can connect you to clinical trial sites, we cannot answer questions about any investigational therapy through email. Your consent to receiving emails is not a requirement to participate in a clinical trial or study. For more information, including how to unsubscribe at any time, see our Privacy Notice & Cookies Policy.

Locations

Site US00003 Karmanos Cancer Institute

Detroit, United States, 48201

Site US00005 University of Michigan Medical Center

Ann Arbor, United States, 48109

Site CA00009 London Health Sciences Centre

London, Canada, N6A 4L6

Site US00001 Seattle Cancer Care Alliance

Seattle, United States, 98109

Site US00002 Memorial Sloan-Kettering Cancer Center

New York, United States, 10065

Site CA00006 Cross Cancer Institute

Edmonton, Canada, T6G 1Z2

Site CA00007 Jewish General Hospital

Montreal, Canada, H3T 1E2

Site US00004 Roswell Park Cancer Institute

Buffalo, United States, 14263

Site CA00008 British Columbia Cancer Agency

Vancouver, Canada, V5Z 4E6

The purpose of this website is to offer education and information to patients and their families and friends, the public, and healthcare professionals about the clinical trial process. In addition, the website will provide specific information about Astellas clinical trials. Please read the complete Astellas Transparency Policy to learn about the clinical trial information available on this website

© ASTELLAS PHARMA GLOBAL DEVELOPMENT, INC.

POWERED BY:

Pharma Intelligence logo